Hepavance Dosage/Direction for Use

HEPAVANCE should be administered on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal).
For chronic hepatitis B virus infection in nucleoside inhibitor-treatment-naïve adults and adolescents 16 years of age and older is 0.5 mg once daily. The recommended dose in adults and adolescents (at least 16 years of age) with a history of hepatitis B viremia while receiving lamivudine or known lamivudine or telbivudine resistance substitutions rtM204I/V with or without rtL180M, rtL80I/V, or rtV173L is 1 mg once daily.
For adult subjects with renal impairment, the apparent oral clearance of entecavir decreased as creatinine clearance decreased. Dosage adjustment is recommended for patients with creatinine clearance less than 50 mL/min, including patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), as shown in Table 1. The once-daily dosing regimens are preferred. (See Table 1.)

Click on icon to see table/diagram/image

Although there are insufficient data to recommend a specific dose adjustment of HEPAVANCE in pediatric patients with renal impairment, a reduction in the dose or an increase in the dosing interval similar to adjustments for adults should be considered.
No dosage adjustment is necessary for patients with hepatic impairment.
The optimal duration of treatment with HEPAVANCE for patients with chronic hepatitis B virus infection and the relationship between treatment and long-term outcomes such as cirrhosis and hepatocellular carcinoma are unknown.